The diamondback moth, Plutella xylostella (L.), is considered one of the most damaging lepidopteran pests, and it has developed resistance to all conventional insecticide classes in the field. Chlorantraniliprole is the first commercial insecticide that belongs to the new chemical class of diamide insecticides. But, P. xylostella have already shown resistance to chlorantraniliprole in China. After 52 generations of selection with chlorantraniliprole, ∼48.17-fold resistance was observed. The resistant strain showed cross-resistance to flubendiamide (7.29-fold), abamectin (6.11-fold), and cyantraniliprole (3.31-fold). Quantitative real-time polymerase chain reaction analysis showed that the expression of the ryanodine receptor gene was higher in the resistant strain than that in the susceptible strain. Enzyme assays indicated that cytochrome P450 activity in the resistant strain was 4.26 times higher compared with the susceptible strain, whereas no difference was seen for glutathione-S-transferase and esterase. Moreover, the toxicity of chlorantraniliprole in the resistant strain could be synergized by piperonyl butoxide, but not by diethyl maleate, and S,S,S-tributyl phosphorothioate. These results can serve as an important base for guiding the use of insecticide in field and delaying the development of pests that are resistant to the insecticides.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 108 • No. 4